CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Paradigm Biopharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Paradigm Biopharmaceuticals Ltd
Level 15, 500 Collins St
Phone: +61 396295566p:+61 396295566 MELBOURNE, VIC  3000  Australia Ticker: PARPAR
Placed into Administration on 9/30/2026
On 9/30/2026, Paradigm Biopharmaceuticals Limited announced that its Directors had resolved on 9/29/2026 to appoint Christopher Pattinson and Hayden White of FTI Consulting as Joint and Several Voluntary Administrators pursuant to Section 436A of the Corporations Act 2001 (Cth). Following the appointment, the Administrators assumed control of The Company’s business, operations, and assets and began working with key stakeholders to independently assess The Company’s ongoing and future viability, including possible Restructuring options. The first statutory meeting of creditors is expected to take place on 10/9/2026, with meeting notices to be distributed to creditors in advance.
Business Summary
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20266/30/2026Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Managing Director and Executive Chairman of the Board PaulRennie 11/22/2022 5/2/2014
Company Secretary and Chief Financial Officer Abby M.Niven 3/3/2023 3/3/2023
Non-Executive Independent Director Matthew J.Fry 3/4/2024 3/4/2024
Non-Executive Independent Director AmosMeltzer 12/9/2020 12/9/2020

General Information
Outstanding Shares: 584,843,595 (As of 6/30/2026)
Shareholders: 10,322
Stock Exchange: ASX
Fax Number: +61 396295466


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 4, 2026